311 related articles for article (PubMed ID: 24842958)
21. Combining HLA-DR risk alleles and anti-Epstein-Barr virus antibody profiles to stratify multiple sclerosis risk.
Strautins K; Tschochner M; James I; Choo L; Dunn DS; Pedrini M; Kermode A; Carroll W; Nolan D
Mult Scler; 2014 Mar; 20(3):286-94. PubMed ID: 23886832
[TBL] [Abstract][Full Text] [Related]
22. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
Levin LI; Munger KL; Rubertone MV; Peck CA; Lennette ET; Spiegelman D; Ascherio A
JAMA; 2005 May; 293(20):2496-500. PubMed ID: 15914750
[TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr virus is associated with grey matter atrophy in multiple sclerosis.
Zivadinov R; Zorzon M; Weinstock-Guttman B; Serafin M; Bosco A; Bratina A; Maggiore C; Grop A; Tommasi MA; Srinivasaraghavan B; Ramanathan M
J Neurol Neurosurg Psychiatry; 2009 Jun; 80(6):620-5. PubMed ID: 19168469
[TBL] [Abstract][Full Text] [Related]
24. No evidence for intrathecal IgG synthesis to Epstein Barr virus nuclear antigen-1 in multiple sclerosis.
Jafari N; van Nierop GP; Verjans GM; Osterhaus AD; Middeldorp JM; Hintzen RQ
J Clin Virol; 2010 Sep; 49(1):26-31. PubMed ID: 20638898
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus reactivation and multiple sclerosis.
Torkildsen Ø; Nyland H; Myrmel H; Myhr KM
Eur J Neurol; 2008 Jan; 15(1):106-8. PubMed ID: 18042233
[TBL] [Abstract][Full Text] [Related]
26. Schizophrenia is Associated With an Aberrant Immune Response to Epstein-Barr Virus.
Dickerson F; Jones-Brando L; Ford G; Genovese G; Stallings C; Origoni A; O'Dushlaine C; Katsafanas E; Sweeney K; Khushalani S; Yolken R
Schizophr Bull; 2019 Sep; 45(5):1112-1119. PubMed ID: 30462333
[TBL] [Abstract][Full Text] [Related]
27. Epstein-Barr virus antibodies and vitamin D in prospective multiple sclerosis biobank samples.
Salzer J; Nyström M; Hallmans G; Stenlund H; Wadell G; Sundström P
Mult Scler; 2013 Oct; 19(12):1587-91. PubMed ID: 23549431
[TBL] [Abstract][Full Text] [Related]
28. [Evaluation of immunoblot-based assay for detecting Epstein-Barr virus viral capsid antibodies].
Altuğlu I; Aksoy A; Zeytinoğlu A; Orman M
Mikrobiyol Bul; 2010 Apr; 44(2):231-6. PubMed ID: 20549957
[TBL] [Abstract][Full Text] [Related]
29. Heightened Epstein-Barr virus immunity and potential cross-reactivities in multiple sclerosis.
Thomas OG; Haigh TA; Croom-Carter D; Leese A; Van Wijck Y; Douglas MR; Rickinson A; Brooks JM; Taylor GS
PLoS Pathog; 2024 Jun; 20(6):e1012177. PubMed ID: 38843296
[TBL] [Abstract][Full Text] [Related]
30. Performance of the architect EBV antibody panel for determination of Epstein-Barr virus infection stage in immunocompetent adolescents and young adults with clinical suspicion of infectious mononucleosis.
Guerrero-Ramos A; Patel M; Kadakia K; Haque T
Clin Vaccine Immunol; 2014 Jun; 21(6):817-23. PubMed ID: 24695777
[TBL] [Abstract][Full Text] [Related]
31. A systematic study of Epstein-Barr virus serologic assays following acute infection.
Rea TD; Ashley RL; Russo JE; Buchwald DS
Am J Clin Pathol; 2002 Jan; 117(1):156-61. PubMed ID: 11789721
[TBL] [Abstract][Full Text] [Related]
32. The serological signs of the Epstein-Barr virus (EBV) activity in the elderly.
Ternák G; Szúcs G; Uj M
Acta Microbiol Immunol Hung; 1997; 44(2):133-40. PubMed ID: 9330661
[TBL] [Abstract][Full Text] [Related]
33. Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy.
Rød BE; Wergeland S; Bjørnevik K; Holmøy T; Ulvestad E; Njølstad G; Myhr KM; Torkildsen Ø
Mult Scler Relat Disord; 2023 Nov; 79():105037. PubMed ID: 37804765
[TBL] [Abstract][Full Text] [Related]
34. Risk factors for multiple sclerosis and associations with anti-EBV antibody titers.
Mouhieddine TH; Darwish H; Fawaz L; Yamout B; Tamim H; Khoury SJ
Clin Immunol; 2015 May; 158(1):59-66. PubMed ID: 25805657
[TBL] [Abstract][Full Text] [Related]
35. Disease-Modifying Treatments for Multiple Sclerosis Affect Measures of Cellular Immune Responses to EBNA-1 Peptides.
Dungan L; Dunne J; Savio M; Kalaszi M; McElheron M; Lynagh Y; O'Driscoll K; Roche C; Qureshi A; Crowley B; Conlon N; Kearney H
Neurol Neuroimmunol Neuroinflamm; 2024 May; 11(3):e200217. PubMed ID: 38547427
[TBL] [Abstract][Full Text] [Related]
36. High prevalence of immunoglobulin A antibody against Epstein-Barr virus capsid antigen in adult patients with lupus with disease flare: case control studies.
Chen CJ; Lin KH; Lin SC; Tsai WC; Yen JH; Chang SJ; Lu SN; Liu HW
J Rheumatol; 2005 Jan; 32(1):44-7. PubMed ID: 15630723
[TBL] [Abstract][Full Text] [Related]
37. Seroepidemiology of EBV and interpretation of the "isolated VCA IgG" pattern.
De Paschale M; Agrappi C; Manco MT; Mirri P; Viganò EF; Clerici P
J Med Virol; 2009 Feb; 81(2):325-31. PubMed ID: 19107979
[TBL] [Abstract][Full Text] [Related]
38. [Epstein-Barr virus antibodies in blood serum of patients with laryngeal cancer].
Morshed K; Polz-Dacewicz M; Szymański M; Ziaja M; Gołabek W
Otolaryngol Pol; 2002; 56(1):45-8. PubMed ID: 12053667
[TBL] [Abstract][Full Text] [Related]
39. Evaluating the Clinical Utility of Epstein-Barr Virus Antibodies as Biomarkers in Multiple Sclerosis: A Systematic Review.
Bose A; Khalighinejad F; Hoaglin DC; Hemond CC
Mult Scler Relat Disord; 2024 Apr; 84():105410. PubMed ID: 38401201
[TBL] [Abstract][Full Text] [Related]
40. Serological Evidence for the Association Between Epstein-Barr Virus Infection and Sjögren's Syndrome.
Xuan J; Ji Z; Wang B; Zeng X; Chen R; He Y; Rao P; Wu P; Shi G
Front Immunol; 2020; 11():590444. PubMed ID: 33193425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
